Form D · Biotechnology

Apexigen, Inc.

San Carlos, CA · CIK 0001814140

Offering snapshot reported Feb 14, 2023 · SEC filing

Reported sold
$5.59M
Offering amount: $5.59M
Investors reported
13
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jan 30, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 14, 2023Initial$5,587,982No comparison13SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$196K
Finders' fees
$45K (estimated)
Form D file number
021-473368
The Total Offering Amount includes up to $2,793,991.20 to be received upon exercise of warrants.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Brookline Capital Markets, a division of Arcadia Securities, LLC44656

Source: Form D, filed Feb 14, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Herb Cross Director
William Duke, Jr. Executive
Jakob Dupont Director
Frank Hsu Executive
Meenu Karson Director
Gordon Ringold Director
Francis Sarena Executive
Scott Smith Director
Samuel Wertheimer Director
Amy Wong Executive
Xiaodong Yang Director, Executive
Dan Zabrowski Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
75 Shoreway Road, Suite C
San Carlos, CA, 94070